Sumitomo Mitsui Financial Group Inc. Sells 334 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Sumitomo Mitsui Financial Group Inc. trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 4.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,698 shares of the financial services provider’s stock after selling 334 shares during the quarter. Sumitomo Mitsui Financial Group Inc.’s holdings in iShares Biotechnology ETF were worth $886,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Arete Wealth Advisors LLC boosted its holdings in iShares Biotechnology ETF by 4.2% in the 4th quarter. Arete Wealth Advisors LLC now owns 1,990 shares of the financial services provider’s stock valued at $263,000 after purchasing an additional 80 shares during the period. TD Private Client Wealth LLC boosted its stake in iShares Biotechnology ETF by 3.0% during the fourth quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock valued at $363,000 after buying an additional 81 shares during the period. Cullen Frost Bankers Inc. grew its position in iShares Biotechnology ETF by 1.5% during the fourth quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after buying an additional 82 shares in the last quarter. Transcend Capital Advisors LLC increased its stake in iShares Biotechnology ETF by 0.8% in the 4th quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock worth $1,449,000 after acquiring an additional 92 shares during the last quarter. Finally, Chicago Partners Investment Group LLC raised its holdings in shares of iShares Biotechnology ETF by 2.5% in the 4th quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock valued at $510,000 after acquiring an additional 94 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 5.4 %

IBB stock opened at $117.16 on Monday. The company’s 50 day moving average is $134.95 and its 200 day moving average is $138.05. The stock has a market cap of $5.28 billion, a price-to-earnings ratio of 24.21 and a beta of 0.84. iShares Biotechnology ETF has a 1-year low of $114.32 and a 1-year high of $150.57.

iShares Biotechnology ETF Increases Dividend

The business also recently disclosed a dividend, which was paid on Friday, March 21st. Stockholders of record on Tuesday, March 18th were issued a dividend of $0.1212 per share. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date was Tuesday, March 18th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.